Clinical trial
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.
NCT02746744 is registered in ClinicalTrials.gov with Anders Svenningsson as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.
- Lead sponsor
- Anders Svenningsson
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2016
- Completion date
- August 31, 2021
- Enrollment
- 200 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.